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tal fees will necessarily increase tremendously; proven ef-
ficacy for these costs has not been provided in Greece yet.
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TREATMENT OF ACUTE OTITIS MEDIA IN A 
MANAGED CARE POPULATION
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2PharMetrics, Inc, Boston, MA, USA
OBJECTIVES: To assess treatment patterns and treat-
ment-related costs of acute otitis media (AOM) in a Man-
aged Care population.
METHODS: All subjects diagnosed with AOM in Phar-
Metrics’ Integrated Outcomes Database between January
1, 1997 and December 31, 1998 were eligible for inclu-
sion. Subjects were classified as: AOM with major surgery,
AOM with minor surgery, or AOM with no surgery. Sub-
ject demographics, AOM—related utilization and costs,
and antibiotic prescriptions were measured during the
study period.
RESULTS: 322,626 subjects were included in the study,
with 97% falling into the AOM with no surgery category.
Approximately 50% of the subjects were 6 years of age or
older, while 52% of the subjects were female. The total
cost of treating AOM for these subjects was $76 million.
Minor and major surgery for AOM was more prevalent in
children aged 6 or older than any other age group, and
was associated with substantially higher costs. In 1997,
the mean cost for subjects undergoing major surgery was
$4,114 (std dev  3,290) compared to $142 (std dev 
335) for subjects not requiring surgery. The most com-
monly prescribed antibiotic overall was amoxicillin, fol-
lowed by sulfamethoxazole/trimethoprim; however, pre-
scribing patterns differed across AOM categories and age
groups.
CONCLUSIONS: Acute Otitis Media is a prevalent con-
dition associated with significant medical costs.
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OBJECTIVES: To use routine data to study outcomes of
all knee and hip joint replacements in an unselected popu-
lation with universal coverage of healthcare.
METHODS: The study population was all resident in Tay-
side, Scotland from 1989–1995. Joint replacements, and
subsequent hospitalizations were identified from a hospital
discharge database. Death was recorded from a community
health database. The electronic records were validated
against primary case records for a random sample.
RESULTS: We identified 1,649 people who had first pri-
mary hip replacement and 989 first primary knee replace-
ments. Case note validation was performed for 274 pa-
tients, of whom 143 had no previous record of hip or knee
surgery and 131 had previous surgery. The proportion of
valid cases was higher in the patients with no previous sur-
gery (98% vs 57%). The most common mis-classification
was revision arthroplasty as primary arthroplasty because
of incomplete recording of previous joint replacement.
There were 353 deaths in the hip implant cohort (21.4%)
and 187 deaths in the knee implant cohort (18.9%); 6.4%
of hip recipients and 5.5% of knee recipients died within the
first year of implant. Four percent of hip replacements were
for management of hip fracture and they had significantly
reduced survival compared to the remaining patients (deaths
at 60 days, 1.6% vs. 0.8%). Significantly more knee recipi-
ents than hip recipients required revision of the joint re-
placement (4.4% vs 2.4%, p  0.007). Although time to
hip implant revision varied with the year of first implant
(with 1990 recipients showing the shortest time to revision),
this effect did not occur among knee implant recipients.
CONCLUSIONS: This study demonstrates the suitability
of the Scottish Morbidity record for postmarket surveil-
lance of medical device implants. The electronic data come
from a stable population with universal medical coverage
and outcomes can be validated by review of primary case
records.
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OBJECTIVES: Research on quality of life (QoL) of pa-
tients cured in childhood from malignant tumors. Wide us-
age of the latest anti-tumor methods of treatment has led
to considerable growth of the number of recovered pa-
tients during the last years. Only in Moscow between
1978–97 2255 children with oncological diseases were
successfully cured, 278 (12,3%) who had retroperitoneal
malignant tumors. Among these children 191 were cured
from nefroblastoma, 66 – from neuroblastoma, 21 – from
adrenal tumors. Antitumor treatment deeply affects the
child’s organism, causing not only physical dysfunction,
but also dramatic psychological, emotional and social
changes in the patient’s life. QoL research of the people
who suffered from malignant tumors in childhood is a new
area in Russian children’s oncology.
